Efficacy of Concurrent Chemoradiotherapy for Patients With Locally Recurrent or Advanced Inoperable Breast Cancer

Concurrent CRT with capecitabine, paclitaxel, or cisplatin/etoposide for recurrent or advanced inoperable breast cancer is well tolerated with impressive clinical response rates and durable local control.